

Title (en)
METHOD OF TREATING INTESTINAL DISORDERS

Title (de)
VERFAHREN ZUR BEHANDLUNG VON INTESTINALEN STÖRUNGEN

Title (fr)
PROCEDE POUR TRAITER DES TROUBLES INTESTINAUX

Publication
EP 0732938 A4 19970319 (EN)

Application
EP 95902712 A 19941201

Priority
• AU 9400745 W 19941201
• AU PM274093 A 19931201
• AU PM832594 A 19940921

Abstract (en)
[origin: WO9515179A1] The present invention provides a method of treating or preventing in a subject an intestinal disorder caused by an elevated level of TNF in the lumen of the intestine of the subject. The method involves administering to the subject an agent which reduces the action of the intraluminal TNF or reduces the production or accumulation of intraluminal TNF. The agent may be any of a number of known anti-TNF agents, however, it is preferred that the agent is an anti-TNF antibody. It is also preferred that the agent is administered directly into the intestine.

IPC 1-7
A61K 39/395

IPC 8 full level
A61K 38/00 (2006.01); **A61K 31/445** (2006.01); **A61K 31/52** (2006.01); **A61K 38/44** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 1/00** (2006.01); **A61P 1/10** (2006.01); **A61P 25/04** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/12** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01); **C07K 16/24** (2006.01)

CPC (source: EP)
A61P 1/00 (2017.12); **A61P 1/10** (2017.12); **A61P 25/04** (2017.12); **A61P 29/00** (2017.12); **A61P 31/04** (2017.12); **A61P 31/12** (2017.12); **A61P 31/18** (2017.12); **A61P 35/00** (2017.12); **A61P 37/00** (2017.12); **A61P 37/08** (2017.12); **A61P 43/00** (2017.12); **C07K 16/241** (2013.01); **A61K 38/00** (2013.01)

Citation (search report)
• [A] EP 0526905 A2 19930210 - YEDA RES & DEV [IL]
• [A] WO 9214455 A1 19920903 - UNIV ROCKEFELLER [US]
• [A] KIMBERLEY J. VAN ZEE ET AL.,: "Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo", PROC. NATL. ACAD. SCI. USA, vol. 89, - June 1992 (1992-06-01), pages 4845 - 4849, XP002022372
• [A] MOHLER K. M. ET AL.,: "Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carrier and TNF antagonists", J. IMMUNOL., vol. 151, no. 3, 1 August 1993 (1993-08-01), pages 1548 - 1561, XP002022440
• See references of WO 9515179A1

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9515179 A1 19950608; CA 2177570 A1 19950608; EP 0732938 A1 19960925; EP 0732938 A4 19970319; JP H09505812 A 19970610

DOCDB simple family (application)
AU 9400745 W 19941201; CA 2177570 A 19941201; EP 95902712 A 19941201; JP 51529995 A 19941201